Past Reports

Summary Quite suddenly industry insiders, analysts and media are recasting beleaguered “car rental” plays into lucrative “fleet management” plays, CRUCIAL to the futures of Uber/Lyft. Icahn owns 35% of HTZ...

Summary Dillard’s appears set up for “infinity squeeze” like VW in 2008, which sent stock up 5x. Einhorn was short VW in 2008, but is now largest outside holder of...

Summary ARA’s JV partners are suddenly exercising their put options nearly as fast as they vest, requiring ARA to buy out their equity stakes. The reasons are becoming clear. Post...

Summary In over 100 articles I have seldom used the word fraud to describe concerns. I reserve that word for the very worst situations where I have the highest confidence....

Summary On Tuesday, Cemtrex fell 13% on huge volume. On the preceding trading day, Cemtrex’s banker Source Capital quietly had its SEC and FINRA registrations terminated following multiple violations. Over...

Summary Shares of YRD have been shunned by traditional China smart money. Outside ownership is dominated by a few US “quant funds” who perform little fundamental research. Existing concerns have...

Summary From November to December, Live Ventures tripled on the back of aggressive paid promotions. Promoters have been paid as much as $2 million to hype Live Ventures. Same promoters...

Summary Bone Growth Stimulators (“BGS”) comprise the largest segment of revenue and more than half of profits, while also driving growth at Orthofix. Other segments are lower margin, commodity businesses...

Summary Nymox withheld the data that Phase 3 trials of its only drug had failed for 6-12 months after management knew of the failure. During this time, Nymox issued bullish...

Bristow is down by 80% since mid 2015 as bankruptcy fears continue to slowly play out. The moderate recovery in oil prices has been unable to help Bristow recover. Bristow...

Summary OraSure dipped just slightly from its 2016 highs on a recent report from Raymond James downgrading OraSure to a “Market Perform”. The report completely dismissed significant near-term problems for...

Summary Since I last highlighted fraud concerns at Osiris, the stock has fallen by 40%. I expect an additional 50% drop based on new catalysts. The CEO has since resigned...

Summary In 2014, CEC pulled an accounting gimmick in order to remain “financially responsible” in the eyes of the Department of Education (“ED”). Calculations indicate that CEC’s failure to sell...

Summary Revance has soared 50% to all-time highs based on preliminary data from a Phase 2 study, which appeared to indicate that its RT002 was superior to Allergan’s Botox. Revance...

Summary Tokai’s attempt at a Phase 3 trial is based on data from just 6 patients out of 87 in Phase 2, based on after-the-fact cherry picking of data. Tokai...

Summary IPO’d at $18 with 100% of shares coming from insiders cashing out (company received no proceeds). Stock fell immediately and has now fallen by 33%. Company is saddled with...

Summary Omeros recently spiked on release of new Phase II drug data for OMS-721. The stock quickly gave up almost all of these gains once the details of this trial...

Summary Shares of Flotek soared by as much as 46% on what looked like a surprise earnings beat. However the “beat” was a result of a single customer who accounted...

Summary A new proposed ruling by the IRS looks set to disqualify SunCoke’s income for MLP purposes. This very subtle change is just now being spotted by more savvy investors...

Summary Air Media rebounded on Tuesday as retail investors “played the bounce” in anticipation of a company response. After the company responded on Wednesday, the stock opened lower, traded down...